Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) Sees Large Increase in Short Interest

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) was the recipient of a large increase in short interest in the month of November. As of November 30th, there was short interest totalling 20,200 shares, an increase of 37.4% from the November 15th total of 14,700 shares. Based on an average daily volume of 19,000 shares, the short-interest ratio is presently 1.1 days. Currently, 0.6% of the company’s stock are short sold.

Cryo-Cell International Stock Performance

Shares of NYSEAMERICAN:CCEL traded down $0.07 during mid-day trading on Friday, reaching $7.84. 6,563 shares of the stock were exchanged, compared to its average volume of 11,139. Cryo-Cell International has a one year low of $4.47 and a one year high of $9.50. The company has a market cap of $63.15 million, a PE ratio of -7.39 and a beta of 0.49.

Cryo-Cell International (NYSEAMERICAN:CCEL) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $0.13 earnings per share for the quarter, topping the consensus estimate of $0.02 by $0.11. The company had revenue of $8.07 million during the quarter. Cryo-Cell International had a negative net margin of 28.03% and a negative return on equity of 42.06%.

Cryo-Cell International Announces Dividend

The firm also recently declared a — dividend, which was paid on Friday, November 29th. Shareholders of record on Friday, November 15th were given a dividend of $0.25 per share. The ex-dividend date of this dividend was Friday, November 15th. Cryo-Cell International’s dividend payout ratio (DPR) is presently -94.34%.

Hedge Funds Weigh In On Cryo-Cell International

An institutional investor recently raised its position in Cryo-Cell International stock. Geode Capital Management LLC increased its stake in shares of Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL) by 68.5% during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 39,860 shares of the company’s stock after acquiring an additional 16,203 shares during the period. Geode Capital Management LLC owned about 0.49% of Cryo-Cell International worth $254,000 as of its most recent filing with the SEC. 10.44% of the stock is currently owned by institutional investors.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.